Q1 Earnings Forecast for Longeveron Issued By HC Wainwright

Longeveron Inc. (NASDAQ:LGVN) – Investment analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Longeveron in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Longeveron’s Q2 2026 earnings at ($0.30) EPS, Q3 2026 earnings at ($0.29) EPS, Q4 2026 earnings at ($0.30) EPS and FY2026 earnings at ($1.20) EPS.

A number of other equities analysts also recently weighed in on the stock. Roth Capital raised shares of Longeveron to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm began coverage on shares of Longeveron in a research report on Friday, December 6th. They issued a “buy” rating and a $10.00 price objective on the stock.

Longeveron Trading Up 5.3 %

LGVN stock opened at $1.40 on Wednesday. The stock has a market cap of $20.77 million, a P/E ratio of -0.22 and a beta of 0.36. The stock’s fifty day simple moving average is $1.64 and its two-hundred day simple moving average is $1.89. Longeveron has a 1-year low of $0.77 and a 1-year high of $6.40.

Institutional Trading of Longeveron

Hedge funds have recently made changes to their positions in the company. State Street Corp bought a new position in shares of Longeveron during the 3rd quarter worth $29,000. Northern Trust Corp purchased a new stake in Longeveron during the fourth quarter valued at about $31,000. Jane Street Group LLC bought a new position in Longeveron during the fourth quarter worth about $35,000. Virtu Financial LLC purchased a new position in shares of Longeveron in the fourth quarter worth about $53,000. Finally, Geode Capital Management LLC grew its stake in Longeveron by 316.0% in the 3rd quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock valued at $250,000 after buying an additional 97,953 shares in the last quarter. 10.01% of the stock is currently owned by institutional investors.

About Longeveron

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.